Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
Denali Therapeutics (NASDAQ:DNLI) Earns Outperform Rating from Analysts at Robert W. Baird
Robert W. Baird assumed coverage on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a research note released on ...
BioSpace13h
HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...
HC Wainwright Has Bullish Forecast for DNLI FY2028 Earnings
HC Wainwright raised their FY2028 earnings per share (EPS) estimates for Denali Therapeutics in a report issued on Tuesday, January 7th. HC Wainwright analyst A. Fein now expects that the company will ...
IMG Biosciences enacts massive lay-offs after Phase I trial failure
Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is cutting 73% of jobs.
BioSpace2h
MyoKardia Alumni Launch Kardigan with $300M to Tackle Heart Disease
After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...
NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration
NervGen is engaged in groundbreaking research in spinal cord injury treatment. Read here for an update on the research's ...